Financial Performance - Yonghe Medical Group reported revenue of RMB 1,688.9 million for the year ended December 31, 2023, with a net loss of RMB 463.1 million[4]. - For the year ending December 31, 2024, Yonghe Medical Group expects revenue to increase to RMB 1,725.9 million, with a projected net loss of RMB 167.3 million[4]. - Chengdu Yonghe reported revenue of RMB 76.8 million for the year ended December 31, 2023, with a net loss of RMB 4.1 million[4]. - For the year ending December 31, 2024, Chengdu Yonghe's revenue is expected to decrease slightly to RMB 75.4 million, with a projected net loss of RMB 2.6 million[4]. Variable Interest Entities - The company has established control over variable interest entities through Beijing Haiyouyou, allowing it to decide on the economic benefits generated[3]. - The service fees from the variable interest entities will be equivalent to the distributable net profits for the specific audited financial year, after deducting any past losses and statutory reserves[3]. Treasury Shares and Capital Management - Yonghe Medical Group plans to utilize treasury shares for various purposes, including employee share schemes and sales, depending on market conditions[5]. - The company emphasizes the importance of capital management in its decision-making regarding treasury shares[5]. Corporate Governance - The board of directors includes key executives such as Chairman Zhang Yu and Executive Directors Zhang Hui and Han Zhi Mei[7]. - The announcement is part of the supplementary information to the annual report for the year ending December 31, 2024, and should be read in conjunction with the annual report[2].
雍禾医疗(02279) - 2025 - 年度业绩